Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia

Phase 1, Investigator And Subject-Blind, Placebo-Controlled, Randomized, Sequential Group, Multiple Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04802540 In Patients With Schizophrenia

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple ascending doses of PF-04802540 administered orally to subjects with schizophrenia.

Inclusion Criteria:

• Males or females of non-childbearing capacity aged 18 to 55 years inclusive
• DSM-IV diagnosis of schizophrenia, stable symptoms for at least 3 months
• Body mass index in the range of 18 to 40 kg/m2 and body weight>45 kg.

Exclusion Criteria:

• Evidence or history of a primary DSM IV axis I diagnosis other than schizophrenia.
• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease
• Any condition possibly affecting drug absorption (eg, gastrectomy).